Canadian Journal of Physiology and Pharmacology · 2008 · 26 citations · 27 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical PharmacologyPharmacodynamicsAntiplatelet TherapyCardiac MedicationsCardiac PharmacotherapyCardiovascular PharmacologyHeart FailureIschemic Heart DiseaseAntiplatelet DrugsCardiac RemodelingCardiac Systolic FunctionCongestive Heart Failure ManagementLeft Ventricular PhysiologyMyocardial Infarction PharmacotherapyPhosphodiesterase InhibitionPost-myocardial Infarction Pharmacotherapy
Antiplatelet agents such as sarpogrelate (SAR), a 5-hydroxytryptamine antagonist, and cilostazol (CIL), a phosphodiesterase-III inhibitor, are used in the management of peripheral vascular disease. In this study, we tested the hypothesis that both SAR and CIL prevent cardiac remodeling and improve cardiac function in congestive heart failure (CHF) due to myocardial infarction (MI). Post-MI rats (3 weeks after the occlusion of coronary artery) received either vehicle (MI+V, n = 36), SAR (MI+SAR; 5 mg xc kg(-1) x day(-1), n = 35) or CIL (MI+CIL; 5 mg x kg(-1) x day(-1), n = 34) from day 21 to day 56. Sham-operated rats (n = 29) served as controls. Electrocardiographic, echocardiographic, and hemodynamic parameters were measured on day 56. Treatment of infarcted animals with SAR or CIL significantly improved the left ventricular (LV) dimensions, LV fractional shortening, cardiac output, stroke volume, mean arterial pressure, LV diastolic function, and LV systolic pressure, as well as rates of LV pressure development and pressure decay. Although cardiac hypertrophy was reduced, both SAR and CIL had no effect on infarct size or MI-associated QTc prolongation. However, SAR decreased whereas CIL increased the incidence of ventricular arrhythmias and the mean number of episodes in infarcted animals. Mortality during the treatment period was decreased by 17% with SAR and increased by 10% with CIL, but these changes were not significant statistically. The data in this study suggest that both SAR and CIL prevent cardiac remodeling and improve cardiac function in MI-induced CHF; however, CIL unlike SAR increased the incidence of arrhythmias and adversely affected patient mortality.
27
Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure
Milton Packer, Joseph R. Carver, Richard J. Rodeheffer et al. · New England Journal of Medicine · 1991 · 2.2K citations · Full text
Medicine, Cardiology, Pharmacology +17
Sharon L. Mulvagh, Miguel A. Quiñones, Neal S. Kleiman et al. · Journal of the American College of Cardiology · 1992 · 215 citations
Medicine, Cardiology, Physiology +15